Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study

IF 2 Q3 HEALTH POLICY & SERVICES
Sana Kagalwalla , Alexander K. Tsai , Michelle Tregear , Andrea Maranda , Damé Idossa , Anne H. Blaes , Helen M. Parsons , Rachel I. Vogel , Arjun Gupta
{"title":"Comparing the time spent in clinic by patients receiving, subcutaneous and intravenous formulations of cancer drugs: A pilot study","authors":"Sana Kagalwalla ,&nbsp;Alexander K. Tsai ,&nbsp;Michelle Tregear ,&nbsp;Andrea Maranda ,&nbsp;Damé Idossa ,&nbsp;Anne H. Blaes ,&nbsp;Helen M. Parsons ,&nbsp;Rachel I. Vogel ,&nbsp;Arjun Gupta","doi":"10.1016/j.jcpo.2025.100625","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Subcutaneous (SC) formulations of cancer-directed and supportive care drugs are associated with time savings relative to their intravenous (IV) formulations in clinical trials, but it is unclear if these time savings apply in routine practice.</div></div><div><h3>Methods</h3><div>We performed a retrospective study of adults with breast cancer treated at a single U.S. academic clinic site in 2024. We matched patients who received (1) SC trastuzumab/pertuzumab, or (2) SC denosumab, 1:1 to patients who received comparator IV formulations (IV trastuzumab/pertuzumab, or IV zoledronic acid, respectively) and had the same number and type of appointment(s) that day. We used Real-time location system (RTLS) badge data to calculate total time spent in the clinic and in the infusion area, and compared these between groups.</div></div><div><h3>Results</h3><div>Among 14 patient-days with SC trastuzumab/pertuzumab and 15 patient-days with SC denosumab matched 1:1 with their IV comparators, most days included other ambulatory services performed (10/14 for SC trastuzumab/pertuzumab, 14/15 for SC denosumab). For trastuzumab/ pertuzumab, the median infusion area time was 65 min for SC vs. 110 min for IV (median difference, 48 min, p &lt; 0.003). The median total clinic time was 166 min for SC vs. 198 min for IV (median difference, 44 min, p = 0.206). For SC denosumab vs IV zoledronic acid, the median total clinic time was 99 min for SC vs. 110 min for IV (median difference, 19 min, p = 0.049).</div></div><div><h3>Conclusion</h3><div>Despite impressive time savings in clinical trials, SC trastuzumab/pertuzumab and SC denosumab offered only modest time savings compared with their IV counterparts when delivered in clinic.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"45 ","pages":"Article 100625"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538325000694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Subcutaneous (SC) formulations of cancer-directed and supportive care drugs are associated with time savings relative to their intravenous (IV) formulations in clinical trials, but it is unclear if these time savings apply in routine practice.

Methods

We performed a retrospective study of adults with breast cancer treated at a single U.S. academic clinic site in 2024. We matched patients who received (1) SC trastuzumab/pertuzumab, or (2) SC denosumab, 1:1 to patients who received comparator IV formulations (IV trastuzumab/pertuzumab, or IV zoledronic acid, respectively) and had the same number and type of appointment(s) that day. We used Real-time location system (RTLS) badge data to calculate total time spent in the clinic and in the infusion area, and compared these between groups.

Results

Among 14 patient-days with SC trastuzumab/pertuzumab and 15 patient-days with SC denosumab matched 1:1 with their IV comparators, most days included other ambulatory services performed (10/14 for SC trastuzumab/pertuzumab, 14/15 for SC denosumab). For trastuzumab/ pertuzumab, the median infusion area time was 65 min for SC vs. 110 min for IV (median difference, 48 min, p < 0.003). The median total clinic time was 166 min for SC vs. 198 min for IV (median difference, 44 min, p = 0.206). For SC denosumab vs IV zoledronic acid, the median total clinic time was 99 min for SC vs. 110 min for IV (median difference, 19 min, p = 0.049).

Conclusion

Despite impressive time savings in clinical trials, SC trastuzumab/pertuzumab and SC denosumab offered only modest time savings compared with their IV counterparts when delivered in clinic.
比较患者接受、皮下和静脉注射抗癌药物制剂的临床时间:一项初步研究
背景:在临床试验中,针对癌症和支持治疗药物的皮下(SC)制剂与静脉(IV)制剂相比可节省时间,但尚不清楚这些时间节省是否适用于常规实践。方法:我们对2024年在美国一个学术诊所接受治疗的成年乳腺癌患者进行了回顾性研究。我们将接受(1)SC曲妥珠单抗/帕妥珠单抗或(2)SC denosumab的患者与接受比较物IV制剂(分别为静脉曲妥珠单抗/帕妥珠单抗或静脉唑来膦酸)的患者进行了1:1的匹配,并且当天有相同的预约次数和类型。我们使用实时定位系统(RTLS)徽章数据来计算在诊所和输液区域花费的总时间,并在两组之间进行比较。结果在SC曲妥珠单抗/帕妥珠单抗的14个患者日和SC地诺单抗的15个患者日中,大多数天数包括其他门诊服务(SC曲妥珠单抗/帕妥珠单抗为10/14,SC地诺单抗为14/15)。对于曲妥珠单抗/帕妥珠单抗,SC组的中位输注时间为65 min,而IV组为110 min(中位差为48 min, p <; 0.003)。SC组的中位总临床时间为166 min,而IV组为198 min(中位差为44 min, p = 0.206)。对于SC denosumab vs IV唑来膦酸,SC和IV的中位总临床时间分别为99 min和110 min(中位差为19 min, p = 0.049)。尽管在临床试验中节省了令人印象深刻的时间,但在临床交付时,与静脉注射相比,曲妥珠单抗/帕妥珠单抗和替诺单抗仅节省了适度的时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信